Ongoing, recruitingTherapeutic exploratory (Phase II)Interventional

A Two-Cohort, Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of Vixarelimab Compared with Placebo in Patients with Idiopathic Pulmonary Fibrosis and in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

At a glance

Status

Ongoing, recruiting

Phase

Therapeutic exploratory (Phase II)

Sponsor

Genentech Inc.

Enrolment target

134

Start

01 Aug 2023

1. Absolute change from baseline to Week 52 in FVC (mL)

Age 18 Years to any · Sex: All

Always speak to your GP or specialist before deciding to take part in a study.